A study on 16 patients (male: 14; ages of 50-78) with the primary polycythemia vera treated by the specific guidelines has shown that the number of erythrocyte in patients with polycythemia vera after a duration of suffering the disease was increased, followed by gradual reduction and was at low level at last. The specific clinical signs can change comprised the number of hypertension can be reduced, the number of thrombocyte, and leukocyte can be slightly increased and should be treated in the first stage and second stage but should not be treated in the third stage
Polycythemia Vera ; Erythrocytes

MPS comprised 4 disease's forms, such as: Chronic myelogenous leukemia (CLM), polycythemia vera (PV), essential thrombocytothemia (ET) and idiopathic myelofibrosis (IMF). From 1985 to May-2001 at Friendship hospital, authors have followed up a group of 86 patients with MPS and some remarks had been drawn out: Some disease's forms of MPS can transform each other, such as: +PV transformed in to CML: 10.00%; +PV transformed in to ET: 16.67%; +IMF transformed in to CML: 66.67%; +ET transformed in to CLM: 8.0%. Some case in MPS, although have not yet truly transformed, but have some changes, as such: +ET with concomitantly increasing erythrocytes: 4.0%; +IMF with concomitantly increasing platelets: 33.33%; +CML with concomitantly increasing platelets: 21.43%; Authors have also mentioned many interesting issues about the way of transformation, the last diagnosis for those disease's forms and the prognosis of these transformations
Leukemia, Myeloid ; Polycythemia Vera ; Syndrome

In 242 subjects (68 female, 174 male), ELISA technique was performed with the set of ORGANON TEKNIKA UNIFORM II. Result showed a HBeAg positive rate of 37.42% on HBsAg positive subjects. The rate of HBsAg positive subjects having anti HBsAg is 56.61%. In 38.9% of B viral hepatitis patients, recession of the condition was noted on laboratory examinations
Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Diseases ; Liver Diseases

120 normal subjects without bleeding history aged 20-77 were studied. Bleeding time 169 seconds, there is no significant statistic difference in genders and age groups. Plasma fibrinogen level was 2.56 g/l, no significant difference in 2 genders. In the under 45 years old group, fibrinogen level was lower than in above 45 yeas old group with statistical significant. No case of non-contracted blood clot occured, 2.5% of blood clot was contrated non completely, 97.5% completely. Alcohol test was negative in all cases. No case of fibrinolyse time < 90 minutes occured.
Hemostasis ; Blood Coagulation ; Laboratories

For more than 15 years (1985 - 2000), there were 8100 blood transfusions performed at the H÷u NghÞ Hospital using 9486 blood units/products (average 1.17 blood units per case). Blood transfusion need of patients, frequency of transfused blood group, features of canceled blood and percentage of transfused blood amount of departments were followed. The results showed that the need of blood transfusion was raising. Group O blood was the most used and group AB was least used. Departments of Surgery, Clinical Hematology, Intensive Care and Hemodialysis used abundant blood transfusion for pathological conditions, including gastric and intestinal conditions, leukemia, myelodysplasia syndrome and bone marrow failure.
Blood transfusion ; hospitals

From 26 patients with bone marrow failure, we had drawn some following remarks:- Over 50% of the patients is in the ages from 61 to 75 years old. (youngest: 42: oldest: 82 years old).- There were 38.46% of the patients that were used to contact with some causes of AA in their history particalarly 11.54%- using cloramphenicol; and 7.69% used to live in the area with American orange toxicant. - 100% of the patient with anemia; 15.36% with anemia + hemorrhage; then anemia + infection (7.69%) and anemia + hemorrahage + infection(7.69%).
Bone Marrow Diseases ; diagnosis ; Epidemiologic Studies

We had drawn out some following remarks from the our studied group of patients with bone marrow failure; - There are 89.29% patients with bone marrow failure in three blood cell lineages; and 35.71% of the patients is servere aplastic anemia. - 14.29% patients with bone marrow failure were finished in the diagnosis of acute leukemia(M1= 50%, M2= 50%). - The persentages of the patients with bone marrow failure died from infection (37.5%) and hemorrhage (50.0%) are still high. Almost of the patients were died in the stage from 24 months to 48 months after having the diagnosis.
Bone Marrow Diseases ; diagnosis ; bone marrow

The general structure of the cluster of differentiation of antigens is divided in to 4 groups including transmembrane proteins type I, II, III and glycosylphosphatidyl inositol-anchored proteins (GPI). The cluster of differentiation plays an important role in both physiological and pathological hematology. This paper introduced some applications of cluster of differentiation in hematology and classification of acute leukemia such as myeloid acute leukemia, lymphoid acute leukemia and biphenotypic acute leukemia
Leukemia ; antigens

From 1987 to 1997 at Friendship Hospital, 34 patients with non-Hodgkin's Lymphomas (NHL) were treated by various schemata such as COP, COPP, CHOP, and CHOP + Bleo. In this study, the authors had drawn some valuable conclusions about the results of the treatment with chemotherapeutic schemata as well as various malignant grades. The study also mentioned the relapse and some complications that happened in the process of treatment of the patients with NHL.
Lymphoma, Non-Hodgkin ; therapeutics

The erythrocyte-antigen, basically is antigen of blood group systems, and usually has 2 parts: protein and lipid or glucid. The erythrocyte antigens usually exist along the life. However, they can be impaired when a person is aging or suffering from a disease. The erythrocyte antibodies are immunoglobulines in the plasma. Most of them are IgM, IgG and little with IgA. Currently, 23 erythrocyte blood group systems with more than 250 antigens have been found.
Erythrocytes ; Antigen-Antibody Complex